DrugPatentWatch Database Preview
Ibrutinib - Generic Drug Details
What are the generic drug sources for ibrutinib and what is the scope of ibrutinib freedom to operate?
Ibrutinib
is the generic ingredient in one branded drug marketed by Pharmacyclics Inc and is included in two NDAs. There are twenty-nine patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.Ibrutinib has two hundred and forty-one patent family members in thirty-eight countries.
There are sixteen drug master file entries for ibrutinib. One supplier is listed for this compound.
Summary for ibrutinib
International Patents: | 241 |
US Patents: | 29 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 2 |
Drug Master File Entries: | 16 |
Suppliers / Packagers: | 1 |
Bulk Api Vendors: | 62 |
Clinical Trials: | 251 |
Patent Applications: | 384 |
Formulation / Manufacturing: | see details |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ibrutinib |
DailyMed Link: | ibrutinib at DailyMed |
Pharmacology for ibrutinib
Drug Class | Kinase Inhibitor |
Mechanism of Action | Protein Kinase Inhibitors |
Synonyms for ibrutinib
(R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one |
(R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-ylprop-2-en-1-one |
1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one |
1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one |
1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]-2-propen-1-one |
1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one |
1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)pyrazolo[3, 4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one |
1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidyl]prop-2-en-1-one |
1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one |
1-{(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl}prop-2-en-1-one |
1X70OSD4VX |
2-Propen-1-one, 1-((3R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo(3,4-d)pyrimidin-1-yl)-1-piperidinyl)- |
2-Propen-1-one, 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]- |
936563-96-1 |
A1-01649 |
AB0008168 |
ABP000965 |
AC-26942 |
ACN-030256 |
AJ-91306 |
AK133084 |
AKOS022185476 |
AMX10219 |
AN-1333 |
AOB87789 |
AX8254580 |
BDBM50357312 |
CHEBI:76612 |
CHEMBL1873475 |
CRA 032765 |
CRA-032765 |
D09KTS |
D10223 |
DB09053 |
EBD2165770 |
EX-5960 |
EX-A066 |
FT-0696693 |
GTPL6912 |
HSDB 8260 |
HY-10997 |
Ibrutinib (BTK inhibitor) |
Ibrutinib (JAN/USAN) |
Ibrutinib (PCI-32765) |
Ibrutinib (PCI32765) |
Ibrutinib [USAN:INN] |
Ibrutinib(PCI-32765) |
Ibrutinib/PCI-32765 |
ibrutinibum |
IMBRUVICA |
Imbruvica (TN) |
J-523872 |
JNJ 02 |
KB-79777 |
KIN0000174 |
KS-000002KE |
MFCD20261150 |
MLS006010041 |
MolPort-027-806-955 |
NCGC00187912-01 |
NCGC00187912-02 |
NCGC00187912-03 |
Pc-32765 |
PCI 32765 |
PCI-32765 |
PCI-32765 (Ibrutinib) |
PCI-32765-00 |
PCI-32765(Ibrutinib) |
PCI32765 |
QC-4573 |
S-7810 |
SC-96633 |
SCHEMBL201859 |
SMR004701213 |
UNII-1X70OSD4VX |
X7513 |
XYFPWWZEPKGCCK-GOSISDBHSA-N |
ZINC35328014 |
US Patents and Regulatory Information for ibrutinib
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pharmacyclics Inc | IMBRUVICA | ibrutinib | CAPSULE;ORAL | 205552-001 | Nov 13, 2013 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
Pharmacyclics Inc | IMBRUVICA | ibrutinib | CAPSULE;ORAL | 205552-002 | Dec 20, 2017 | RX | Yes | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
Pharmacyclics Inc | IMBRUVICA | ibrutinib | TABLET;ORAL | 210563-002 | Feb 16, 2018 | RX | Yes | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
International Patents for ibrutinib
Country | Document Number | Estimated Expiration |
---|---|---|
Morocco | 41654 | ➤ Try a Free Trial |
New Zealand | 717373 | ➤ Try a Free Trial |
South Africa | 201007561 | ➤ Try a Free Trial |
Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for ibrutinib
Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|
90021-0 | Sweden | ➤ Try a Free Trial | PRODUCT NAME: IBRUTINIB ELLER ETT FARMACEUTISKT GODTAGBART SALT DAERAV; REG. NO/DATE: EU/1/14/945 20141023 |
692 | Luxembourg | ➤ Try a Free Trial | PRODUCT NAME: IBRUTINIB, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI. FIRST REGISTRATION: 20141023 |
2015017,C2201840 | Lithuania | ➤ Try a Free Trial | PRODUCT NAME: IBRUTINIBAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/14/945 20141021 |
Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
For more information try a trial or see the plans and pricing
Serving hundreds of leading biopharmaceutical companies globally:









Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.